SUO 2023: Dr. Stratton previews prostate cancer research
Kelly L. Stratton, MD, FACS, highlights 5 noteworthy prostate cancer abstracts set to be presented at the 24th Annual Meeting of the Society of Urologic Oncology.
In this video, Kelly L. Stratton, MD, FACS, highlights 5 noteworthy prostate cancer abstracts set to be presented at the 24th Annual Meeting of the Society of Urologic Oncology from November 28-December 1, 2023 in Washington, DC. Stratton is an assistant professor of urologic oncology and an adjunct assistant professor of medical oncology at the University of Oklahoma, Oklahoma City.
Throughout the discussion, he highlights the following abstracts:
- Poster 34 (Siva et al): Clinical Outcomes Of Patients On Active Surveillance For Low-Risk Prostate Cancer With Small Index Lesions On MRI
- Poster 188 (Bochner et al): MRI-Guided Transurethral Ultrasound Ablation (TULSA) Of Localized Prostate Cancer: Single Institution Experience Of Treatment Efficacy
- Poster 27 (Ahmed et al): Early Adverse Events, Emergency Room Visits And Hospitalizations After PSMA Based RLT: A Retrospective Analysis From Real World Theranostics Practice
- Poster 28 (Ahmed et al): Tolerability Of Lutetium-177–PSMA-617 In Men With Prostate Cancer And Baseline Cytopenia
- Poster 249 (Ricaurte-Fajardo et al): Assessment Of PSMA Pet Imaging Response In Metastatic Castration-Resistant Prostate Cancer After 225AC-J591 Therapy: Post-Hoc Patient-Level Analysis Of A Prospective Clinical Trial
The management of high-risk localized prostate cancer: Back to the future
April 5th 2024"I predict the future treatment for men with truly high-risk prostate cancer will see a fusion of what was thought to be standard local treatments combined with multimodality therapies that were initially impactful only in the more advanced disease state," writes Michael S. Cookson, MD, MMHC, FACS.
Subcutaneous nivolumab meets coprimary pharmacokinetic end points for ccRCC
January 30th 2024Patients in the subcutaneous arm (n = 242) achieved a geometric mean Cavgd28 of 77.373μl/mL (90% CI, 74.555-80.297) compared with 36.875 μl/mL (90% CI, 35.565-38.235) in the IV arm (n = 245), for a geometric mean ratio of 2.098 μl/mL (90% CI, 2.001-2.200).
